Endometrial pathologies in clinical follow-up of patients with hormone receptor-positive/negative breast cancer

Clinical experience in endometrial pathologies at a tertiary center

Authors

Keywords:

breast cancer, endometrial pathologies, tamoxifen

Abstract

Background/Aim: Breast cancer is the leading cause of cancer-related fatalities in women. Tamoxifen, a selective estrogen receptor modulator (SERM), is frequently employed for chemoprevention in hormone receptor (HR)-positive breast cancer patients due to its anti-estrogenic impact on breast tissue. Nevertheless, tamoxifen exhibits agonistic effects on the endometrium, particularly in postmenopausal women. This study aims to assess gynecological issues and endometrial pathologies that emerge during the treatment and follow-up phases of women diagnosed with HR-positive/negative breast cancer.

Methods: This cohort study involved a data review from 857 breast cancer patients diagnosed over a decade at a tertiary center. Histopathological endometrial findings were evaluated for 166 patients who underwent gynecological consultations before breast cancer treatment with normal examination results and underwent invasive assessments due to gynecological symptoms that arose during treatment and follow-up. The study encompassed cases culminating in total abdominal hysterectomy and bilateral salpingo-oophorectomy (TAH+BSO).

Results: The study analyzed 166 cases meeting the inclusion criteria. The mean age at breast cancer diagnosis was 48 years with a standard deviation of 8.4 years, and the average follow-up duration was 4.1 (3.8) years. The predominant histopathological type was invasive ductal carcinoma (75.3%). Of the cases, 68.6% occurred during premenopausal and 31.4% during postmenopause. HR positivity was identified in 136 cases (81.9%), while 30 (18.1%) exhibited negative HR status. Among HR-positive cases, 113 (83.0%) received tamoxifen treatment, while 23 (17.0%) were treated with letrozole. Common clinical findings during and after treatment encompassed increased endometrial thickness (ET) and abnormal uterine bleeding (AUB). Histopathological evaluation of invasive procedures prompted by increased ET indicated the following frequent endometrial findings: proliferative endometrium (33.1%), endometrial polyp (20.5%), and endometrial hyperplasia (EH) without atypia (9%). The histopathological outcomes of invasive procedures prompted by AUB included atrophic endometrium (11.4%), proliferative endometrium (3.6%), and endometrial cancer (1.8%). Among the endometrial malignancies, three occurred in the premenopausal phase and four in the postmenopausal phase. Notably, three of the seven endometrial malignancies were observed in the tamoxifen hormone therapy group, all HR-positive. Four cases were from the non-tamoxifen hormone therapy group with negative HR status.

Conclusion: Globally, breast cancer ranks as the most prevalent malignancy in women. Tamoxifen, a frequently utilized adjuvant therapy post breast cancer surgery, can exert diverse effects on gynecological organs, encompassing benign pathologies like increased ET and malignant pathologies like uterine neoplasia. There is a rising suspicion that etiopathogenetic factors contributing to breast cancer progression might also precipitate uterine cancer, irrespective of tamoxifen use. Vigilant patient monitoring is paramount for detecting uterine neoplasia and other gynecological pathologies.

Downloads

Download data is not yet available.

References

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021 May 4;71(3):209–49. DOI: https://doi.org/10.3322/caac.21660

Kesson EM, Allardice GM, George WD, Burns HJG, Morrison DS. Effects of multidisciplinary team working on breast cancer survival: retrospective, comparative, interventional cohort study of 13 722 women. BMJ. 2012 Apr 26;344(apr26 1):e2718–e2718. DOI: https://doi.org/10.1136/bmj.e2718

Jordan VC. The SERM Saga, Something from Nothing: American Cancer Society/SSO Basic Science Lecture. Ann Surg Oncol. 2019 Jul 25;26(7):1981–90. DOI: https://doi.org/10.1245/s10434-019-07291-1

Emons G, Mustea A, Tempfer C. Tamoxifen and Endometrial Cancer: A Janus-Headed Drug. Cancers (Basel). 2020 Sep 7;12(9):2535. DOI: https://doi.org/10.3390/cancers12092535

Fleming CA, Heneghan HM, O’Brien D, McCartan DP, McDermott EW, Prichard RS. Meta-analysis of the cumulative risk of endometrial malignancy and systematic review of endometrial surveillance in extended tamoxifen therapy. British Journal of Surgery. 2018 Jul 11;105(9):1098–106. DOI: https://doi.org/10.1002/bjs.10899

Freeman EW, Sammel MD, Gracia CR, Kapoor S, Lin H, Liu L, et al. Follicular phase hormone levels and menstrual bleeding status in the approach to menopause. Fertil Steril. 2005 Feb;83(2):383–92. DOI: https://doi.org/10.1016/j.fertnstert.2004.06.066

Giaquinto AN, Sung H, Miller KD, Kramer JL, Newman LA, Minihan A, et al. Breast Cancer Statistics, 2022. CA Cancer J Clin. 2022 Nov 3;72(6):524–41. DOI: https://doi.org/10.3322/caac.21754

Yin L, Duan JJ, Bian XW, Yu S cang. Triple-negative breast cancer molecular subtyping and treatment progress. Breast Cancer Research. 2020 Dec 9;22(1):61. DOI: https://doi.org/10.1186/s13058-020-01296-5

Cheng WF, Lin HH, Torng PL, Huang SC. Comparison of Endometrial Changes among Symptomatic Tamoxifen-Treated and Nontreated Premenopausal and Postmenopausal Breast Cancer Patients. Gynecol Oncol. 1997 Aug;66(2):233–7. DOI: https://doi.org/10.1006/gyno.1997.4739

Cohen I, Altaras MM, Shapira J, Tepper R, Rosen DJD, Cordoba M, et al. Time-Dependent Effect of Tamoxifen Therapy on Endometrial Pathology in Asymptomatic Postmenopausal Breast Cancer Patients. International Journal of Gynecological Pathology. 1996 Apr;15(2):152–7. DOI: https://doi.org/10.1097/00004347-199604000-00010

Runowicz CD, Costantino JP, Wickerham DL, Cecchini RS, Cronin WM, Ford LG, et al. Gynecologic conditions in participants in the NSABP breast cancer prevention study of tamoxifen and raloxifene (STAR). Am J Obstet Gynecol. 2011 Dec;205(6):535.e1-535.e5. DOI: https://doi.org/10.1016/j.ajog.2011.06.067

Şahin Uysal N, Boyraz G, Usubütün A, Tuncer ZS. The evaluation of laparotomy results in breast cancer patients with gynecological pathologies. Journal of Obstetrics and Gynaecology Research. 2020 Oct 10;46(10):2126–33. DOI: https://doi.org/10.1111/jog.14408

Jeon J, Kim SE, Lee DY, Choi D. Factors associated with endometrial pathology during tamoxifen therapy in women with breast cancer: a retrospective analysis of 821 biopsies. Breast Cancer Res Treat. 2020 Jan 20;179(1):125–30. DOI: https://doi.org/10.1007/s10549-019-05448-w

Cohen I. Endometrial pathologies associated with postmenopausal tamoxifen treatment. Gynecol Oncol. 2004 Aug;94(2):256–66. DOI: https://doi.org/10.1016/j.ygyno.2004.03.048

Lee SC, Kaunitz AM, Sanchez-Ramos L, Rhatigan RM. The Oncogenic Potential of Endometrial Polyps. Obstetrics & Gynecology. 2010 Nov;116(5):1197–205. DOI: https://doi.org/10.1097/AOG.0b013e3181f74864

Fisher B, Costantino JP, Redmond CK, Fisher ER, Wickerham DL, Cronin WM. Endometrial Cancer in Tamoxifen-Treated Breast Cancer Patients: Findings From the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14 *. JNCI: Journal of the National Cancer Institute. 1994 Apr 6;86(7):527–37. DOI: https://doi.org/10.1093/jnci/86.7.527

Romero SA, Young K, Hickey M, Su HI. Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen. Cochrane Database of Systematic Reviews. 2020 Dec 21;2021(2). DOI: https://doi.org/10.1002/14651858.CD007245.pub4

Feldman S, Shapter A, Welch WR, Berkowitz RS. Two-Year Follow-Up of 263 Patients with Post/Perimenopausal Vaginal Bleeding and Negative Initial Biopsy. Gynecol Oncol. 1994 Oct;55(1):56–9. DOI: https://doi.org/10.1006/gyno.1994.1247

F. Machado, J.R. Rodríguez(h), J.P.H. León, J.R. Rodríguez, J.J. Parrilla, L. Abad. Tamoxifen and endometrial cancer. Is screening necessary? A review of the literature. Eur J Gynaecol Oncol . 2005;26(3):257–65.

Committee Opinion No. 601. Obstetrics & Gynecology. 2014 Jun;123(6):1394–7. DOI: https://doi.org/10.1097/01.AOG.0000450757.18294.cf

Guo J, Zhang Y, Qian H, Ma F, Cui X, Duan H. The clinical characteristics and prognosis of endometrial carcinomas that occur after breast cancer: does hormone receptor status of breast cancer matter? Arch Gynecol Obstet. 2019 Nov 1;300(5):1399–404. DOI: https://doi.org/10.1007/s00404-019-05318-2

Lortet-Tieulent J, Ferlay J, Bray F, Jemal A. International Patterns and Trends in Endometrial Cancer Incidence, 1978–2013. JNCI: Journal of the National Cancer Institute. 2018 Apr 1;110(4):354–61. DOI: https://doi.org/10.1093/jnci/djx214

Liu J, Jiang W, Mao K, An Y, Su F, Kim BYS, et al. Elevated risks of subsequent endometrial cancer development among breast cancer survivors with different hormone receptor status: a SEER analysis. Breast Cancer Res Treat. 2015 Apr 13;150(2):439–45. DOI: https://doi.org/10.1007/s10549-015-3315-5

Engin H. High-grade endometrial stromal sarcoma following tamoxifen treatment. Gynecol Oncol. 2008 Jan;108(1):253–4. DOI: https://doi.org/10.1016/j.ygyno.2007.09.002

Kloos I, Delaloge S, Pautier P, Di Palma M, Goupil A, Duvillard P, et al. Tamoxifen-related uterine carcinosarcomas occur under/after prolonged treatment: Report of five cases and review of the literature. International Journal of Gynecological Cancer. 2002 Sep;12(5):496–500. DOI: https://doi.org/10.1046/j.1525-1438.2002.01134.x

Yildirim Y, Inal MM, Sanci M, Yildirim YK, Mit T, Polat M, et al. Development of uterine sarcoma after tamoxifen treatment for breast cancer: report of four cases. International Journal of Gynecological Cancer. 2005 Nov;15(6):1239–42. DOI: https://doi.org/10.1111/j.1525-1438.2005.00170.x

Downloads

Published

2023-12-07

Issue

Section

Research Article

How to Cite

1.
Kurt S, Ozmen S, Yavuz O, Ilgen O, Ulukus EC. Endometrial pathologies in clinical follow-up of patients with hormone receptor-positive/negative breast cancer: Clinical experience in endometrial pathologies at a tertiary center. J Surg Med [Internet]. 2023 Dec. 7 [cited 2024 Jul. 23];7(12):754-9. Available from: https://jsurgmed.com/article/view/7583